Drug Trial Radar · NCT05171075
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
417
Actual
Start
Sep 27, 2022
Primary completion
Apr 10, 2026
Study completion Apr 10, 2026
Sponsor
- Lead sponsor
- Anthos Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Novartis Pharmaceuticals
- First posted
- Dec 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)
Conditions
- Venous Thromboembolism
- Deep Venous Thrombosis
- Pulmonary Embolism
Interventions
AbelacimabBiological
Abelacimab 150 mg
DalteparinDrug
Dalteparin 200 IU/kg/day followed by 150 IU/kg/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first event of centrally adjudicated VTE recurrenceTime frame: up to 6 months
Locations
117 sites in 20 countries. Site status is shown where the registry gives one.
Washington DC VAMC
Washington D.C., District of Columbia
NorthShore University Health System
Evanston, Illinois
Barnes-Jewish Hospital
St Louis, Missouri
Memorial Sloan Kettering Cancer Center-Middletown
Middletown, New Jersey
Memorial Sloan Kettering Cancer Center-Commack
Commack, New York
Memorial Sloan Kettering Cancer Center-West Harrison
Harrison, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Weill Cornell Medical College
New York, New York
Duke University Medical Center
Durham, North Carolina
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Blacktown Hospital
Blacktown, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Northern Health
Epping, Victoria, Australia
LK Wiener Neustadt
Neustadt, Austria
Medical University of Vienna
Vienna, Austria
University of Calgary
Calgary, Canada
Sault Area Hospital
Marie, Canada
Toronto General Hospital
Toronto, Canada
Hamilton Health Sciences, Juravinski Hospital and Cancer Centre
Hamilton, Ontario, Canada
Ottawa Hospital Research Instituite
Ottawa, Ontario, Canada
Ottawa Hospital Research Instituite
Ottawa, Ontario, Canada
Beijing Shijitan Hosp.
Beijing, China
Peking University Third Hospital
Beijing, China
Jilin Province Tumor Hospital
Ch’ang-ch’un, China
Southern Medical University - Zhujiang Hospital
Guangdong, China
Nanfang Hospital of Southern Medical University
Guangzhou, China
The Sixth Affiliated Hospital of Sun Yat-Sen University
Guangzhou, China
Huizhou Municipal Central Hospital
Huizhou, China
Nanjing First Hospital
Nanjing, China
Nantong Tumor Hospital (Tumor Hospital Affiliated to Nantong University )
Tongzhou, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
Union Hospital Tongji Medical College Huazhong University of Science &Technology
Wuhan, China
Hubei Cancer Hospital
Wuhan, China
The Second Hospital of Jiaxing
Zhejiang, China
Masarykuv onkologicky ustav
Brno, Czechia
University Hospital Hradec Kralove
Hradec Králové, Czechia
Onkologická klinika VFN a 1. LF UK
Prague, Czechia
Thomayerova nemocnice
Prague, Czechia
CHU Angers - Hôpital Hôtel Dieu
Angers, France
CHU Clermont Ferrand - Hopital Gabriel Montpied
Clermont-Ferrand, France
Showing 40 of 117 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.